Gilead Sciences (NASDAQ:GILD) Price Target Raised to $159.00 at Rothschild & Co Redburn

Gilead Sciences (NASDAQ:GILD) had its price target boosted by Rothschild & Co Redburn from $153.00 to $159.00 in a research note released on Tuesday morning,MarketScreener reports. Rothschild & Co Redburn currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently weighed in on the company. BMO Capital Markets reissued an “outperform” rating on shares of Gilead Sciences in a report on Tuesday, January 13th. Truist Financial initiated coverage on Gilead Sciences in a research report on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective for the company. TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Morgan Stanley decreased their target price on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. Finally, Citigroup upped their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.52.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $2.61 during trading on Tuesday, hitting $126.75. 663,085 shares of the company’s stock traded hands, compared to its average volume of 6,290,973. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The firm’s fifty day moving average price is $123.53 and its 200 day moving average price is $118.29. The company has a market cap of $157.26 billion, a PE ratio of 19.60, a PEG ratio of 0.66 and a beta of 0.33. Gilead Sciences has a twelve month low of $91.84 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were given a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the transaction, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This represents a 1.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 136,757 shares of company stock valued at $16,951,612. 0.27% of the stock is currently owned by company insiders.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. SOA Wealth Advisors LLC. grew its holdings in shares of Gilead Sciences by 8.7% in the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 81 shares in the last quarter. Trivium Point Advisory LLC increased its stake in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after purchasing an additional 83 shares in the last quarter. Binnacle Investments Inc raised its holdings in Gilead Sciences by 11.8% during the 3rd quarter. Binnacle Investments Inc now owns 785 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 83 shares during the period. Rothschild Investment LLC raised its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after purchasing an additional 84 shares during the period. Finally, Hemington Wealth Management lifted its holdings in shares of Gilead Sciences by 9.3% in the third quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.